New RSV vaccine for moms shields newborns from severe illness
NCT ID NCT06813872
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 28 times
Summary
This study looks at how well the ABRYSVO vaccine works when given to pregnant people to protect their babies from RSV, a leading cause of serious lung infections in infants. Researchers will analyze medical records of infants up to 6 months old in Western Pennsylvania over several RSV seasons. The goal is to confirm the vaccine's real-world effectiveness in preventing hospitalizations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUSES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.